Literature DB >> 21846727

E46K human alpha-synuclein transgenic mice develop Lewy-like and tau pathology associated with age-dependent, detrimental motor impairment.

Kristel L Emmer1, Elisa A Waxman, Jason P Covy, Benoit I Giasson.   

Abstract

Synucleinopathies are a group of neurodegenerative disorders associated with the formation of aberrant amyloid inclusions composed of the normally soluble presynaptic protein α-synuclein (α-syn). Parkinson disease is the most well known of these disorders because it bears α-syn pathological inclusions known as Lewy bodies (LBs). Mutations in the gene for α-syn, including the E46K missense mutation, are sufficient to cause Parkinson disease as well as other synucleinopathies like dementia with LBs. Herein, we describe transgenic mice expressing E46K human α-syn in CNS neurons that develop detrimental age-dependent motor impairments. These animals accumulate age-dependent intracytoplasmic neuronal α-syn inclusions that parallel disease and recapitulate the biochemical, histological, and morphological properties of LBs. Surprisingly, the morphology of α-syn inclusions in E46K human α-syn transgenic mice more closely resemble LBs than the previously described transgenic mice (line M83) that express neuronal A53T human α-syn. E46K human α-syn mice also develop abundant neuronal tau inclusions that resemble neurofibrillary tangles. Subsequent studies on the ability of E46K α-syn to induce tau inclusions in cellular models suggest that both direct and indirect mechanisms of protein aggregation are probably involved in the formation of the tau inclusions observed here in vivo. Re-evaluation of presymptomatic transgenic mice expressing A53T human α-syn reveals that the formation of α-syn inclusions in mice must be synchronized; however, inclusion formation is diffuse within affected areas of the neuroaxis such that there was no clustering of inclusions. Collectively, these findings provide insights in the mechanisms of formation of these aberrant proteinaceous inclusions and support the notion that α-syn aggregates are involved in the pathogenesis of human diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21846727      PMCID: PMC3186371          DOI: 10.1074/jbc.M111.247965

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  90 in total

1.  Genetic analysis of families with Parkinson disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein.

Authors:  A Athanassiadou; G Voutsinas; L Psiouri; E Leroy; M H Polymeropoulos; A Ilias; G M Maniatis; T Papapetropoulos
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

2.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

3.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.

Authors:  P Damier; E C Hirsch; Y Agid; A M Graybiel
Journal:  Brain       Date:  1999-08       Impact factor: 13.501

4.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.

Authors:  M Baba; S Nakajo; P H Tu; T Tomita; K Nakaya; V M Lee; J Q Trojanowski; T Iwatsubo
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

5.  Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation.

Authors:  Q Zheng-Fischhöfer; J Biernat; E M Mandelkow; S Illenberger; R Godemann; E Mandelkow
Journal:  Eur J Biochem       Date:  1998-03-15

6.  Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism.

Authors:  K Markopoulou; Z K Wszolek; R F Pfeiffer; B A Chase
Journal:  Ann Neurol       Date:  1999-09       Impact factor: 10.422

7.  Widespread alterations of alpha-synuclein in multiple system atrophy.

Authors:  D W Dickson; W Liu; J Hardy; M Farrer; N Mehta; R Uitti; M Mark; T Zimmerman; L Golbe; J Sage; A Sima; C D'Amato; R Albin; S Gilman; S H Yen
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

8.  Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance?

Authors:  A Papadimitriou; V Veletza; G M Hadjigeorgiou; A Patrikiou; M Hirano; I Anastasopoulos
Journal:  Neurology       Date:  1999-02       Impact factor: 9.910

Review 9.  Diagnostic criteria for Parkinson disease.

Authors:  D J Gelb; E Oliver; S Gilman
Journal:  Arch Neurol       Date:  1999-01

10.  Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes.

Authors:  C F Lippa; H Fujiwara; D M Mann; B Giasson; M Baba; M L Schmidt; L E Nee; B O'Connell; D A Pollen; P St George-Hyslop; B Ghetti; D Nochlin; T D Bird; N J Cairns; V M Lee; T Iwatsubo; J Q Trojanowski
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

View more
  70 in total

1.  Amyloidogenic α-synuclein seeds do not invariably induce rapid, widespread pathology in mice.

Authors:  Amanda N Sacino; Mieu Brooks; Michael A Thomas; Alex B McKinney; Nicholas H McGarvey; Nicola J Rutherford; Carolina Ceballos-Diaz; Janice Robertson; Todd E Golde; Benoit I Giasson
Journal:  Acta Neuropathol       Date:  2014-05       Impact factor: 17.088

2.  Selective Neuronal Vulnerability in Alzheimer's Disease: A Network-Based Analysis.

Authors:  Jean-Pierre Roussarie; Vicky Yao; Patricia Rodriguez-Rodriguez; Rose Oughtred; Jennifer Rust; Zakary Plautz; Shirin Kasturia; Christian Albornoz; Wei Wang; Eric F Schmidt; Ruth Dannenfelser; Alicja Tadych; Lars Brichta; Alona Barnea-Cramer; Nathaniel Heintz; Patrick R Hof; Myriam Heiman; Kara Dolinski; Marc Flajolet; Olga G Troyanskaya; Paul Greengard
Journal:  Neuron       Date:  2020-06-29       Impact factor: 17.173

3.  Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.

Authors:  Zachary A Sorrentino; Niran Vijayaraghavan; Kimberly-Marie Gorion; Cara J Riffe; Kevin H Strang; Jason Caldwell; Benoit I Giasson
Journal:  J Biol Chem       Date:  2018-10-16       Impact factor: 5.157

Review 4.  Immune system responses in Parkinson's disease: Early and dynamic.

Authors:  Malú G Tansey; Marina Romero-Ramos
Journal:  Eur J Neurosci       Date:  2018-12-10       Impact factor: 3.386

Review 5.  The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration.

Authors:  Danielle E Mor; Malcolm J Daniels; Harry Ischiropoulos
Journal:  Mov Disord       Date:  2019-01-11       Impact factor: 10.338

6.  Presynaptic alpha-synuclein aggregation in a mouse model of Parkinson's disease.

Authors:  Kateri J Spinelli; Jonathan K Taylor; Valerie R Osterberg; Madeline J Churchill; Eden Pollock; Cynthia Moore; Charles K Meshul; Vivek K Unni
Journal:  J Neurosci       Date:  2014-02-05       Impact factor: 6.167

7.  Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of α-Synuclein Fibrils.

Authors:  Jacob I Ayers; Mieu M Brooks; Nicola J Rutherford; Jasie K Howard; Zachary A Sorrentino; Cara J Riffe; Benoit I Giasson
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

8.  E46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation.

Authors:  Ignacio Íñigo-Marco; Miguel Valencia; Laura Larrea; Ricardo Bugallo; Mikel Martínez-Goikoetxea; Iker Zuriguel; Montserrat Arrasate
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

Review 9.  Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.

Authors:  Xuling Li; Simon James; Peng Lei
Journal:  J Mol Neurosci       Date:  2016-09-15       Impact factor: 3.444

10.  Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.

Authors:  Jason R Cannon; Kindiya D Geghman; Victor Tapias; Thomas Sew; Michelle K Dail; Chenjian Li; J Timothy Greenamyre
Journal:  Exp Neurol       Date:  2012-11-12       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.